Research ArticleLaboratory Studies
Pharmacokinetics of Chimeric L6 Conjugated to Indium-111- and Yttrium-90-DOTA-Peptide in Tumor-Bearing Mice
Sally J. DeNardo, Gao-Ren Zhong, Qansy Salako, Min Li, Gerald L. DeNardo and Claude F. Meares
Journal of Nuclear Medicine May 1995, 36 (5) 829-836;
Sally J. DeNardo
Gao-Ren Zhong
Qansy Salako
Min Li
Gerald L. DeNardo
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Pharmacokinetics of Chimeric L6 Conjugated to Indium-111- and Yttrium-90-DOTA-Peptide in Tumor-Bearing Mice
Sally J. DeNardo, Gao-Ren Zhong, Qansy Salako, Min Li, Gerald L. DeNardo, Claude F. Meares
Journal of Nuclear Medicine May 1995, 36 (5) 829-836;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Does Paclitaxel (Taxol) Given after 111In-Labeled Monoclonal Antibodies Increase Tumor-Cumulated Activity in Epithelial Cancers?
- Preclinical Evaluation of Cathepsin-degradable Peptide Linkers for Radioimmunoconjugates
- Cilengitide Targeting of {alpha}v{beta}3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts
- In Vivo Biodistribution of a Humanized Anti-Lewis Y Monoclonal Antibody (hu3S193) in MCF-7 Xenografted BALB/c Nude Mice
- Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts